Abstract
Acute Lymphoblastic Leukaemia (ALL) is the most frequent paediatric cancer. Modern therapies have improved survival rates, but approximately 15-20 % of patients relapse. At present, patients’ risk of relapse are assessed by projecting high-dimensional flow cytometry data onto a subset of biomarkers and manually estimating the shape of this reduced data. Here, we apply methods from topological data analysis (TDA), which quantify shape in data via features such as connected components and loops, to pre-treatment ALL datasets with known outcomes. We combine these fully unsupervised analyses with machine learning to identify features in the pre-treatment data that are prognostic for risk of relapse. We find significant topological differences between relapsing and non-relapsing patients and confirm the predictive power of CD10, CD20, CD38, and CD45. Further, we are able to use the TDA descriptors to predict patients who relapsed. We propose three prognostic pipelines that readily extend to other haematological malignancies.
Teaser Topology reveals features in flow cytometry data which predict relapse of patients with acute lymphoblastic leukemia
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been partially supported by the Fundación Española para la Ciencia y la Tecnología (FECYT project PR214), the Asociación Pablo Ugarte (APU, Spain), Junta de Andalucía (Spain) group FQM-201, Junta de Comunidades de Castilla-La Mancha (grant number SBPLY/17/180501/000154), the Programme of Research and Transfer Promotion from the University of Cádiz (grant number EST2020-025), Ministery of Science and Technology, Spain (grant number PID2019-110895RB-I00, funded by MCIN/AEI/10.13039/501100011033). This work was also subsidized by a grant for the research and biomedical innovation in the health sciences within the framework of the Integrated Territorial Initiative (ITI) for the province of Cádiz (grant number ITI-0038-2019). ITI is 80\% co-financed by the funds of the FEDER Operational Program of Andalusia 2014-2020 (Council of Health and Families). BJS and HMB aremembers of the Centre for Topological Data Analysis, funded by the EPSRC grant (EP/R018472/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Hospital Universitario de Jeréz de la Frontera gave ethical approval for this work. IRB of Hospital Infantil Universitario Niño Jesús gave ethical approval for this work. IRB of Hospital Universitario Vírgen del Rocío gave ethical approval for this work. IRB of Hospital Clínico Universitario Vírgen de la Arrixaca gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Implementation details, code and processed PH data are freely available on https://github.com/salvadorchulian/shapecancerrelapse. Flow cytometry files are available upon request. These datasets can be provided by the corresponding author, S.C., or H.B., pending scientific review and a completed material transfer agreement. Requests for the datasets should be submitted to: S.C., or H.B.. All other data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.
